
Robert E Ariano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/967296/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	An updated vancomycin dosing protocol for initiating therapy in patients undergoing intermittent high-flux hemodialysis. American Journal of Health-System Pharmacy, 2022, , .	0.5	2
2	Evaluation of Transfusion Practices in Noncardiac Surgeries at High Risk for Red Blood Cell Transfusion: A Retrospective Cohort Study. Transfusion Medicine Reviews, 2021, 35, 16-21.	0.9	6
3	Variation in prophylactic tranexamic acid administration among anesthesiologists and surgeons in orthopedic surgery: a retrospective cohort study. Canadian Journal of Anaesthesia, 2021, 68, 962-971.	0.7	3
4	Prophylactic tranexamic acid use in non ardiac surgeries at high risk for transfusion. Transfusion Medicine, 2021, 31, 236-242.	0.5	4
5	Efficacy and Safety of Tranexamic Acid in Major Non-Cardiac Surgeries at High Risk for Transfusion: A Systematic Review and Meta-Analysis. Transfusion Medicine Reviews, 2020, 34, 51-62.	0.9	24
6	Clinical Blood Isolates from Hemodialysis Patients: Distribution of Organisms and Antimicrobial Resistance, 2007-2014. Canadian Journal of Hospital Pharmacy, 2020, 73, 266-271.	0.1	0
7	The Pharmacokinetics and Pharmacodynamics of Carfentanil After Recreational Exposure: A Case Report. Pharmacotherapy, 2018, 38, e41-e45.	1.2	35
8	Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis. Journal of Antimicrobial Chemotherapy, 2018, 73, 1888-1894.	1.3	18
9	Evaluation of cefazolin antimicrobial prophylaxis during cardiac surgery with cardiopulmonary bypass. Journal of Antimicrobial Chemotherapy, 2018, 73, 768-771.	1.3	14
10	Antimicrobial Prophylaxis for Patients Undergoing Cardiac Surgery: Intraoperative Cefazolin Concentrations and Sternal Wound Infections. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	19
11	Evaluation of cefazolin antimicrobial prophylaxis during cardiac surgery with cardiopulmonary bypass—authors' response. Journal of Antimicrobial Chemotherapy, 2018, 73, 2588-2588.	1.3	0
12	No role for patient body weight on renal function assessment for drug dosing. Journal of Antimicrobial Chemotherapy, 2017, 72, 1802-1811.	1.3	3
13	Microbiological Trends and Antimicrobial Resistance in Peritoneal Dialysis-Related Peritonitis, 2005 to 2014. Peritoneal Dialysis International, 2017, 37, 170-176.	1.1	35
14	EXTENDED INTERVAL GENTAMICIN DOSING IN PRETERM INFANTS LESS THAN 35â€WEEKS CORRECTED GESTATIONAL AGE. Archives of Disease in Childhood, 2016, 101, e1.52-e1.	1.0	0
15	Once-daily aminoglycosides. American Journal of Health-System Pharmacy, 2016, 73, 529-529.	0.5	0
16	Targeted benefits of prolonged-infusion piperacillin-tazobactam in an <i>in vitro</i> infection model of <i>Pseudomonas aeruginosa</i> . Journal of Chemotherapy, 2016, 28, 390-394.	0.7	15
17	Integrated pharmacokinetic–pharmacodynamic modelling to evaluate antimicrobial prophylaxis in abdominal surgery. Journal of Antimicrobial Chemotherapy, 2016, 71, 2902-2908.	1.3	12
18	Multifaceted antibiotic treatment analysis of methicillin-sensitive Staphylococcus aureus bloodstream infections. International Journal of Antimicrobial Agents, 2016, 48, 674-679	1.1	7

ROBERT E ARIANO

#	Article	IF	CITATIONS
19	Pharmacodynamics of Antimicrobial Prophylaxis in Cardiac Surgery: Association Between Intraoperative Cefazolin Concentrations and Postoperative Infections. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
20	Comparison of Fentanyl and Morphine in the Prehospital Treatment of Ischemic Type Chest Pain. Prehospital Emergency Care, 2016, 20, 45-51.	1.0	17
21	Preoperative therapeutic apheresis for severe medically refractory amiodaroneâ€induced thyrotoxicosis: A case report. Journal of Clinical Apheresis, 2014, 29, 168-170.	0.7	12
22	Post-operative nausea and vomiting in the cardiac surgery population: Who is at risk?. Heart and Lung: Journal of Acute and Critical Care, 2014, 43, 550-554.	0.8	29
23	Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. International Journal of Antimicrobial Agents, 2013, 41, 255-260.	1.1	99
24	Successful Treatment of Pulmonary Blastomycosis with Continuously Infused Amphotericin B Deoxycholate After Failure with Liposomal Amphotericin B. Annals of Pharmacotherapy, 2013, 47, e26-e26.	0.9	9
25	Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD). Journal of Antimicrobial Chemotherapy, 2013, 68, i67-i72.	1.3	21
26	A Single, Ultraâ€High Dose Aminoglycoside Therapy in a Rat Model of E. coli Induced Septic Shock. FASEB Journal, 2013, 27, lb546.	0.2	0
27	Sedation and Analgesia Usage in Severe Pandemic H1N1 (2009) Infection: A Comparison to Respiratory Failure Secondary to Other Infectious Pneumonias. Annals of Pharmacotherapy, 2012, 46, 9-20.	0.9	12
28	Initial Vancomycin Dosing Protocol to Achieve Therapeutic Serum Concentrations in Patients Undergoing Hemodialysis. Clinical Infectious Diseases, 2012, 55, 527-533.	2.9	30
29	Comment: Neuroleptic Malignant Syndrome Versus Serotonin Syndrome: The Search for a Diagnostic Tool. Annals of Pharmacotherapy, 2012, 46, 613-613.	0.9	0
30	The Influence of Sparse Data Sampling on Population Pharmacokinetics: A Post Hoc Analysis of a Pharmacokinetic Study of Morphine in Healthy Volunteers. Clinical Therapeutics, 2012, 34, 668-676.	1.1	8
31	Neuroleptic Malignant Syndrome Versus Serotonin Syndrome: The Search for a Diagnostic Tool. Annals of Pharmacotherapy, 2011, 45, 1165-1165.	0.9	16
32	Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Medicine, 2011, 37, 632-638.	3.9	90
33	Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data. Journal of Antimicrobial Chemotherapy, 2011, 66, 343-349.	1.3	47
34	Preferential Emergence of Reduced Vancomycin Susceptibility in Health Care-Associated Methicillin-Resistant Staphylococcus aureus Isolates during Continuous-Infusion Vancomycin Therapy in an <i>In Vitro</i> Dynamic Model. Antimicrobial Agents and Chemotherapy, 2011, 55, 3627-3630.	1.4	11
35	The use of antiviral agents for the management of severe influenza. Critical Care Medicine, 2010, 38, e43-e51.	0.4	58
36	Should IV Antibiotics Be Administered by Prolonged Infusion?. Canadian Journal of Hospital Pharmacy, 2010, 63, 246-9.	0.1	2

ROBERT E ARIANO

#	Article	IF	CITATIONS
37	Support for higher ciprofloxacin AUC24/MIC targets in treating Enterobacteriaceae bloodstream infection. Journal of Antimicrobial Chemotherapy, 2010, 65, 1725-1732.	1.3	69
38	Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. Cmaj, 2010, 182, 357-363.	0.9	99
39	Population Pharmacokinetics of High-Dose, Prolonged-Infusion Cefepime in Adult Critically III Patients with Ventilator-Associated Pneumonia. Antimicrobial Agents and Chemotherapy, 2009, 53, 1476-1481.	1.4	114
40	Historical Perspectives in Critical Care Medicine: Blood Transfusion, Intravenous Fluids, Inotropes/Vasopressors, and Antibiotics. Critical Care Clinics, 2009, 25, 201-220.	1.0	13
41	Aminoglycoside-Induced Vestibular Injury: Maintaining a Sense of Balance. Annals of Pharmacotherapy, 2008, 42, 1282-1289.	0.9	72
42	Nicotine dose–concentration relationship and pregnancy outcomes in rat: Biologic plausibility and implications for future research. Toxicology and Applied Pharmacology, 2007, 218, 1-10.	1.3	32
43	Prenatal cigarette smoke exposure: Pregnancy outcome and gestational changes in plasma nicotine concentration, hematocrit, and carboxyhemoglobin in a newly standardized rat model. Toxicology and Applied Pharmacology, 2006, 214, 118-125.	1.3	19
44	Are Most Patients on the Labour Floor in Active Labour? A Descriptive Study of a Canadian Obstetrical Unit. Journal of Obstetrics and Gynaecology Canada, 2005, 27, 130-136.	0.3	3
45	An Evaluation of an Optimal Sampling Strategy for Meropenem in Febrile Neutropenics. Journal of Clinical Pharmacology, 2005, 45, 832-835.	1.0	7
46	Obstetric Staffing Challenges. Nursing for Women's Health, 2005, 9, 134-139.	0.2	1
47	Adequacy of a Vancomycin Dosing Regimen in Patients Receiving High-Flux Hemodialysis. American Journal of Kidney Diseases, 2005, 46, 681-687.	2.1	58
48	Evaluating Ciprofloxacin Dosing for Pseudomonas aeruginosa Infection by Using Clinical Outcome-Based Monte Carlo Simulations. Antimicrobial Agents and Chemotherapy, 2005, 49, 4009-4014.	1.4	40
49	Pharmacokinetics and Pharmacodynamics of Meropenem in Febrile Neutropenic Patients with Bacteremia. Annals of Pharmacotherapy, 2005, 39, 32-38.	0.9	168
50	Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. Diagnostic Microbiology and Infectious Disease, 2005, 51, 39-43.	0.8	69
51	Peritoneal Fluid Titer Test for Peritoneal Dialysis-Related Peritonitis. Antimicrobial Agents and Chemotherapy, 2004, 48, 1719-1726.	1.4	5
52	A reevaluation of empiric therapy for peritoneal dialysis-related peritonitis. American Journal of Kidney Diseases, 2004, 44, 559-561.	2.1	4
53	Bayesian Pharmacokinetics of Gentamicin in a Haemodialysis Population. Clinical Pharmacokinetics, 2004, 43, 205-210.	1.6	15
54	Effect of antibiotic sequence on combination regimens against Pseudomonas aeruginosa in a multiple-dose, in vitro infection model. Diagnostic Microbiology and Infectious Disease, 2004, 49, 67-70.	0.8	5

ROBERT E ARIANO

#	Article	IF	CITATIONS
55	Bayesian Pharmacokinetic Analysis of a Gentamicin Nomogram in Neonates: A Retrospective Study. Current Therapeutic Research, 2003, 64, 178-188.	0.5	4
56	Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. Journal of Antimicrobial Chemotherapy, 2003, 52, 668-674.	1.3	130
57	AUC0-t/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. Journal of Antimicrobial Chemotherapy, 2003, 51, 905-911.	1.3	19
58	Antibiotic Pharmacodynamics in Surgical Prophylaxis: an Association between Intraoperative Antibiotic Concentrations and Efficacy. Antimicrobial Agents and Chemotherapy, 2002, 46, 3026-3030.	1.4	124
59	Antibiotic tolerance of peritoneal bacterial isolates in dialysis fluids. Journal of Antimicrobial Chemotherapy, 2002, 49, 863-866.	1.3	13
60	Immunofluorescence imaging as a tool for studying the pharmacokinetics of a human monoclonal single chain fragment antibody. IEEE Transactions on Medical Imaging, 2002, 21, 1317-1323.	5.4	8
61	Challenging the Current Treatment Paradigm for Methicillin-Resistant <i>Staphylococcus Epidermidis</i> Peritonitis in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2002, 22, 335-338.	1.1	26
62	Challenging the current treatment paradigm for methicillin-resistant Staphylococcus epidermidis peritonitis in peritoneal dialysis patients. Peritoneal Dialysis International, 2002, 22, 335-8.	1.1	7
63	Population Pharmacokinetics of Fentanyl in Healthy Volunteers. Journal of Clinical Pharmacology, 2001, 41, 757-763.	1.0	26
64	Evaluation and Management of Drug-Induced Thrombocytopenia in the Acutely Ill Patient. Pharmacotherapy, 2000, 20, 292-307.	1.2	66
65	Failure of danaparoid anticoagulation for cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery, 2000, 119, 167-168.	0.4	7
66	Marked Variation in Peritoneal Insulin Absorption in Peritoneal Dialysis. Peritoneal Dialysis International, 2000, 20, 652-655.	1.1	3
67	Analysis of microbiological trends in peritoneal dialysis–related peritonitis from 1991 to 1998. American Journal of Kidney Diseases, 2000, 36, 1009-1013.	2.1	166
68	Comment: Single Daily Dosing of Aminoglycosides. Annals of Pharmacotherapy, 1994, 28, 1412-1412.	0.9	2
69	Once Daily Aminoglycoside Dosing: Maintained Efficacy with Reduced Nephrotoxicity?. Renal Failure, 1992, 14, 1-9.	0.8	37
70	Lack of in Vitro Inactivation of Tobramycin by Imipenem/Cilastatin. Annals of Pharmacotherapy, 1992, 26, 1075-1077.	0.9	5
71	Exacerbation of Myasthenia Gravis by Norfloxacin. DICP: the Annals of Pharmacotherapy, 1990, 24, 207-208.	0.2	16